AtriCure Inc. priced an underwritten public offering of 2.5 million common shares at $30.75 each.
The company expects to raise net proceeds of about $72 million, which will go toward working capital and other general corporate purposes.
Underwriters have a 30-day option to buy up to 375,000 additional common shares on the same terms and conditions.
The offering is expected to close Oct. 10, subject to customary closing conditions.
J.P. Morgan and Piper Jaffray & Co. are acting as joint book-running managers for the offering, with Canaccord Genuity LLC, Leerink Partners and Stifel, Nicolaus & Co. Inc. as co-managers.
Mason, Ohio-based AtriCure develops technologies to treat irregular heartbeat, which can lead to blood clots, stroke, heart failure and other heart-related complications.